An Act Promoting Equity In Medicaid Coverage For Fertility Health Care.
Summary
HB 7022 would require the Commissioner of Social Services to amend Connecticut’s Medicaid state plan to cover fertility diagnostic care, fertility preservation services, and fertility treatment beginning January 1, 2026. The bill defines those terms broadly to include testing, counseling, medications, procedures, genetic testing, cryopreservation, storage of reproductive material, and fertility treatment intended to achieve a live birth. It also specifically requires coverage for medically necessary ovulation-enhancing drugs and related monitoring services, and at least three cycles of ovulation-enhancing medication treatment.
The bill also directs the Department of Social Services to study and report by July 1, 2026 on the costs and benefits of adding in-vitro fertilization as a covered benefit under fee-for-service Medicaid and any future managed care model. That report must address possible federal Medicaid waivers and the amount of state funding that would be needed. In effect, the bill expands the scope of reproductive health benefits available through HUSKY Health/Medicaid and creates a pathway for possible future IVF coverage.
Impact
The bill would amend the Medicaid state plan and expand covered services under Connecticut’s medical assistance program, known as HUSKY Health, by adding fertility-related diagnostic, preservation, and treatment services. It would affect the Department of Social Services, Medicaid beneficiaries seeking fertility care, and potentially providers and managed care arrangements if IVF is later added as a covered benefit. The bill does not itself mandate IVF coverage immediately, but it requires a formal cost-benefit analysis and federal waiver review that could support future statutory or administrative changes.
Sentiment
The available vote history suggests the bill had meaningful support in committee, passing the Joint Favorable vote 16-6. That margin indicates a generally favorable sentiment toward expanding fertility-related Medicaid coverage, though not unanimous. No committee transcript is available here, so the record does not show detailed debate, but the vote split suggests the proposal was supported by a majority while drawing some opposition or concern from a minority of members.
Contention
The main point of contention appears to be the cost and scope of expanding Medicaid to cover fertility services, especially in-vitro fertilization. The bill’s reporting requirement specifically asks DSS to estimate state funding needs and identify any necessary Medicaid waivers, which suggests fiscal and federal-approval concerns were central. Opponents likely focused on budget impact, program expansion, and whether IVF should be covered immediately, while supporters appear to have emphasized equity in access to fertility care and broader reproductive health coverage for Medicaid recipients.